SCHEMBL10043845

SCHEMBL10043845

Cc1cc2c(cn1)cc(-c1cc(NC(=O)Nc3ccc(F)c(C(F)(F)F)c3)ccc1C)c(=O)n2C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.45
KDR P35968 10/20 0.45
CCR2 P41597 1/20 0.43
CCR5 P51681 1/20 0.43
THRB P10828 1/20 0.43
CSF1R P07333 2/20 0.43
FLT1 P17948 2/20 0.43
FLT4 P35916 2/20 0.43
FLT3 P36888 2/20 0.43
ABL1 P00519 1/20 0.43
LCK P06239 1/20 0.43
LYN P07948 1/20 0.43
KIT P10721 1/20 0.43
SRC P12931 1/20 0.43
BLK P51451 1/20 0.43
CDK8 P49336 2/20 0.42
AR P10275 1/20 0.41
BRAF P15056 4/20 0.41
BLM P54132 1/20 0.40
WRN Q14191 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043839 0.94 SYK (0.47) SYKKDRFLT1LCKCDK8
SCHEMBL10043751 0.91 SYK (0.53) SYKKDRTHRBLCKBRAF
SCHEMBL10043846 0.90 KDR (0.49) SYKKDRFLT3LCKCDK8
SCHEMBL10043848 0.86 SYK (0.48) SYKKDRLCKBRAFRIPK1
SCHEMBL10043828 0.86 RAB9A (0.48) SYKABL1SRCBRAFRAF1
SCHEMBL10043847 0.86 SYK (0.59) SYKKDRCSF1RFLT1FLT4
SCHEMBL10043821 0.84 SYK (0.49) SYKKDRLCKKITSRC
SCHEMBL10043661 0.84 SYK (0.55) SYKKDRLCKBRAFRAF1
SCHEMBL10043873 0.82 SYK (0.44) SYKKDRCCR2CCR5LCK
SCHEMBL10043860 0.82 SYK (0.51) SYKKDRCCR2CCR5ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885KDR 108/4885CCR2 191/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885KDR 108/4885CCR2 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.